PTEN and neoplasm: As it has been reported that tumor cells with PI3K/AKT/mTOR pathway activation are likely to be more sensitive to AKT inhibition [27], baseline PI3K/AKT/mTOR pathway activation status as assessed by PTEN IHC and pAKT IHC was evaluated.